Clinical observation of Bazhen decoction Huaji pill combined with chemoembolization in the treatment of primary liver cancer

Abstract

Objective To observe the clinical effect of Bazhen decoction Huaji pill combined with transcatheter arterial chemoembolization(TACE) in the treatment of primary liver cancer. Methods From December 2016 to October 2017, 76 patients with primary liver cancer admitted to the People's Hospital of Haiyang were selected.According to the different clinical treatment methods, the patients were divided into two groups, with 38 cases in each group.The control group received hepatic arterial chemoembolization, and the observation group received Bazhen decoction Huaji pill combined with TACE. Results The total remission rate of the patients in the observation group was 63.16% (24/38), which was significantly higher than 23.68%(9/38) in the control group (χ2=12.050, P<0.05). The improvement rate and stability rate of KPS score in the observation group were 47.37%(18/38), 36.84%(14/38), respectively, which were higher than those in the control group [26.32%(10/38), 31.58%(12/38), χ2=6.397, P<0.05]. The incidence rate of adverse reactions in the observation group was 21.05%, which was lower than 44.74% in the control group, the difference was significant(χ2=4.828, P<0.05). Conclusion Bazhen decoction Huaji pill combined with TACE in the treatment of patients with primary liver cancer can effectively alleviate the patients' condition, improve the quality of life of patients, and has high safety.It is worthy of popularization and application. Key words: Liver neoplasms; Chemoembolization, therapeutic; Quality of life; Clinical effect; Bazhen Tanghe; Huaji pill; Combined modality therapy; Contrastive study